Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 85 (3), 303-315

Amyloid-β Immunotherapy for Alzheimer Disease: Is It Now a Long Shot?

Affiliations
Review

Amyloid-β Immunotherapy for Alzheimer Disease: Is It Now a Long Shot?

Francesco Panza et al. Ann Neurol.

Abstract

The amyloid-β (Aβ) cascade hypothesis of Alzheimer disease (AD) holds that brain accumulation of Aβ initiates the disease process. Accordingly, drug research has targeted Aβ production, clearance, and deposition as therapeutic strategies. Unfortunately, candidate drugs have failed to show clinical benefit in established, early, or prodromal disease, or in those with high AD risk. Currently, monoclonal antibodies specifically directed against the most neurotoxic Aβ forms are undergoing large-scale trials to confirm initially encouraging results. However, recent findings on the normal physiology of Aβ suggest that accumulation may be compensatory rather than the pathological initiator. If this is true, alternative strategies will be needed to defeat this devastating disease. ANN NEUROL 2019;85:303-315.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

Substances

Feedback